• By ICR Secretariat
  • Posted Thursday, April 22, 2021

Merck, in latest COVID-19 setback, scraps one drug and pins hopes on another

https://www.biopharmadive.com/news/merck-halt-development-covid-drug-oncoimmune-ridgeback/598450/

  • Merck & Co. will halt development of one experimental COVID-19 drug and change the clinical development plan for another, the latest setback to the drugmaker's plans to develop coronavirus treatments and vaccines.